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Abstract
We studied retrospectively the medical records of all patients (n = 150) diagnosed, by cerebrospinal ﬂuid (CSF) analysis, with neurobor-
reliosis (NB) in Jo¨nko¨ping County, Sweden during 2000–2005. The number of NB cases increased from 5/100 000 to 10/100 000 inhab-
itants/year. In 17% of the patients, anti-Borrelia antibodies were found in CSF but not in serum at the time of diagnosis. Facial palsy,
headache and fever were frequent manifestations in children, whereas unspeciﬁc muscle and joint pain were the most commonly
reported symptoms in older patients. Post-treatment symptoms persisting for more than 6 months occurred in 13%, and the patients
concerned were signiﬁcantly older, had longer-lasting symptoms prior to treatment, had higher levels of Borrelia-speciﬁc IgG in CSF, and
more often had radiculitis. The total cost of NB-related healthcare was estimated to be €500 000 for the entire study group (€3300
per patient), and the cost of social beneﬁts was estimated to be €134 000 (€2000 per patient). CSF analysis is necessary for the diagno-
sis of NB, because some patients develop antibodies in serum later than in CSF. Early diagnosis of borreliosis would result in reduced
human suffering and in economic gain.
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Introduction
In Europe, neuroborreliosis (NB) is the most common mani-
festation of disseminated borreliosis, occurring in 14–34% of
all patients with borreliosis [1–3]. The clinical course of NB
is highly variable. In most patients, antibiotic therapy leads to
full recovery, but some patients experience residual or
recurrent symptoms even after treatment [4–8].
In Jo¨nko¨ping County, with an area of 10 475 km2 and
located in the south-east of Sweden (Fig. 1), borreliosis is
known to be endemic. In December 2005, the county had
330 179 inhabitants. The prevalence of Borrelia-infected Ixodes
ticks varies between 10% and 20% [9,10]. The incidence of
human borreliosis in Jo¨nko¨ping County was reported to be
60 cases/100 000 inhabitants/year in 1992–1993 [1]. Of these
cases, 10/100 000/year were considered to be NB.
The aims of this retrospective study were to: (i) monitor
the incidence of NB during 2000–2005; (ii) study how NB
symptoms relate to age; (iii) identify cases with speciﬁc anti-
bodies in cerebrospinal ﬂuid (CSF) but not in serum at diag-
nosis; (iv) search for possible clinical or laboratory markers
associated with the risk of developing long-lasting post-treat-
ment symptoms; and (v) address some economic aspects of
NB in terms of cost of healthcare and social beneﬁts [11].
Materials and Methods
Study population and case deﬁnitions
The population studied comprised all inhabitants in Jo¨nko¨ping
County, from 2000 through 2005. Inclusion criteria were
clearly positive CSF Borrelia-speciﬁc antibody levels (optical
density (OD) >0.40 for both IgG and IgM—see below,
ELISA) or borderline levels (IgG, OD 0.19–0.39; IgM,
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OD 0.16–0.39) (n = 157). All patients ﬁnally included (n =
150) had pleocytosis in the CSF, deﬁned as >5 mononuclear
cells (MNCs)/lL, except for four patients who had
positive or borderline Borrelia-speciﬁc CSF IgG, a positive
Borrelia-speciﬁc IgG index (according to either one or both
of the Borrelia-speciﬁc IgG index calculation methods
described below), and symptoms consistent with active NB.
The four patients had a long history of illness (36 weeks
to several years). One of them responded to antibiotic
treatment, two responded only partially, and one did not
receive any treatment. Seven of the 157 patients were
excluded because of other obvious diagnoses (e.g. normal-
pressure hydrocephalus, cerebellar infarction or Varicella
encephalitis) and/or absence of pleocytosis. In these seven
patients, the anti-Borrelia CSF antibodies were considered
to be an indication of a previous NB infection or IgM
cross-reactivity to another pathogen (e.g. Varicella). The
number of patients included was 150, all of whom had ele-
vated Borrelia-speciﬁc antibodies (IgG and/or IgM) in CSF
and pleocytosis, except in the four cases mentioned above
(Fig. 2).
Laboratory methods
The Laboratory of Microbiology, Ryhov County Hospital,
performed all Borrelia antibody tests, using the commercially
available Lyme Borreliosis ELISA kit (2nd Generation) (Dako
Cytomation A/S, Glostrup, Denmark). From January 2000 to
August 2004, the Borrelia-speciﬁc antibody index was calcu-
lated as described by Peter [12], with the modiﬁcation that
total IgG was substituted for Rubella-speciﬁc IgG. The
formula used was: [Borrelia-speciﬁc IgG in CSF (OD)/Borrelia-
speciﬁc IgG in serum (OD)]/[Rubella-speciﬁc IgG in CSF
(OD)/Rubella-speciﬁc IgG in serum (OD)]. From September
FIG. 1. Jo¨nko¨ping County, Sweden. Each spot refers to a site of domicile.
CSF pleocytosis
n = 148 
No CSF pleocytosis
n = 9 
Other disease
n = 2
NB
n = 146
Other disease
n = 5
NB
n = 4 
Included NB patients
n = 150
Elevated levels of Borrelia-
specific antibodies in CSF
(IgG and/or IgM)
n = 157 
FIG. 2. Inclusion of patients with neuroborreliosis (NB). CSF, cere-
brospinal ﬂuid.
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2004, the laboratory used total IgG as reference molecule:
[Borrelia-speciﬁc IgG in CSF (OD)/Borrelia-speciﬁc IgG in
serum (OD)]/[total IgG in CSF (mg/L)/total IgG in serum
(g/L)]. A Borrelia-speciﬁc antibody index >2 was considered
to indicate intrathecal anti-Borrelia antibody production
detected with both methods.
Data collection
The study was approved by the Regional Ethical Review
Board in Linko¨ping. Permission to read the patients’ medical
records was given by the medical director of each depart-
ment. The medical records were scrutinized retrospectively
by one of the authors (A.J.H.) according to a standardized
protocol.
Data on cost of healthcare were obtained from
the Departments of Economy and Information Technology,
Ryhov County Hospital. Monetary values were assigned to
each hospitalization using the classiﬁcation systems according
to Health Care Financing Administration–Diagnosis Related
Groups during 2000–2003, and NordDRG during 2003–2005
[13,14]. Data on sickness and temporary parental beneﬁts
were provided by the Swedish Social Insurance Agency.
Data handling and statistics
Statistical analyses were performed using SPSS for Windows,
version 15.0. To compare multiple study groups, the Krus-
kal–Wallis ANOVA test was performed, followed by the
Mann–Whitney test as a post hoc analysis. Correlations were
calculated using the Spearman correlation. Trend analysis of
incidence was performed using linear regression. The chi-
square test was used for statistical analysis of categorical
variables, and the Fisher’s exact test was applied when
expected counts were <5. Two-tailed tests were used, and
p-values of <0.05 were considered to be signiﬁcant.
Results
Number of cases/year
During the study period 2000–2005, the annual number of
NB cases, veriﬁed by CSF analysis, increased from 16 to 32
cases/year (5–10/100 000 inhabitants/year) (Fig. 3). Ninety-
three patients (62%) were men, and 57 (38%) were women
(Table 1). The median age was 18 years, with a range from 3
to 87 years (Fig. 3).
Clinical and laboratory ﬁndings prior to treatment
The reported symptoms and their frequencies are presented
in Table 1. Facial palsy, neck pain, fever and fatigue were
more common in patients under the age of 40 years
(p 0.0001–0.031). Patients over 40 years of age reported
muscle and joint pain, radiating pain, paresthesias, vertigo
and concentration problems more often than patients under
40 years of age (p 0.0001–0.003). Patients under 40 years of
age had symptoms of shorter duration prior to diagnosis
than patients over 40 years of age (p <0.0001). A tick bite
had been noticed by 32% of the patients, and 24% had an
erythema migrans.
CSF pleocytosis was dominated by MNCs (median,
164 cells/lL; range, 0–1380 cells/lL). Increased levels of anti-
Borrelia antibodies were found in CSF but not in serum in 25
(17%) of the patients at the time of diagnosis. These patients
had symptoms with a median duration of 3 weeks (range,
1 day to 8 weeks). The CSF albumin/serum albumin ratio, as
an indicator of blood–brain barrier damage, was elevated in
80% of the patients.
CSF lactate was elevated in 55% (range, 1.3–3.9 mM) and
CSF glucose was low in 9% (range, 1.9–8.2 mM). Patients
under the age of 40 years had higher cell counts in CSF than
those over 40 years of age (p <0.0001).
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FIG. 3. (a) Number of cases with neuroborreliosis, veriﬁed by
cerebrospinal ﬂuid analysis, in Jo¨nko¨ping County, Sweden, 2000–
2005. Trend analysis: p = 0.02. (b) Number of cases of neuroborreli-
osis in each age group.
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In general, no abnormalities were found in other routine
blood laboratory parameters, i.e blood cell counts and cre-
atinine, electrolyte, aminotransferase, alkaline phosphatase,
bilirubin or lactate dehydrogenase levels. C-reactive protein
was elevated (>10 mg/L) in six of 99 analysed patients, and
white blood cell counts were elevated (>8.8 · 109/L) in 26
of 98 patients. There were no signiﬁcant differences between
men and women regarding laboratory parameters or dura-
tion of illness before diagnosis.
All four patients with Borrelia-speciﬁc IgG in the CSF and a
positive Borrelia-speciﬁc IgG index, but no pleocytosis, had a
long history of illness (median, 64 weeks; range, 36 weeks to
6 years). They most frequently reported muscle and joint
pain, paresthesia, vertigo and concentration problems. Inter-
estingly, the highest Borrelia-speciﬁc IgG indices were found
among these four patients (range, 2.4–13.1).
Fatigue, fever >38C, headache, facial palsy, neck pain and
muscle and joint pain were most frequently reported in the
patients with the most pronounced pleocytosis (CSF cell
count of >284/lL, the upper quartile), which also correlated
with age <40 years. This group had also signiﬁcantly higher
CSF albumin (p <0.0001), CSF albumin/serum albumin ratios
(p <0.0001) and CSF lactate (p < 0.001), and lower CSF glu-
cose (p < 0.001).
The patients were treated with oral doxycycline (63%),
intravenous ceftriaxone (25%), benzylpenicillin (9%) or cefur-
oxime (1%) for 10–21 days (median, 14 days).
Follow-up
At follow-up, 106 patients had completely recovered, but 44
still had symptoms at the last visit. The 106 patients for whom
the clinical course until recovery was clearly documented
were classiﬁed according to the duration of post-treatment
symptoms (Table 2). Signiﬁcant differences in age distribution
were found among all groups, except when group B was
compared with group C. Higher age was associated with
longer duration of symptoms. The acute-phase symptoms are
presented in Table 3. The only laboratory parameter in the
acute phase that differed signiﬁcantly among the groups was
Borrelia-speciﬁc CSF IgG, which was highest in group D. No
signiﬁcant differences were found among the groups regarding
type of antibiotic treatment or duration of treatment.
Economic aspects
The total healthcare cost for the patients in the study group
was estimated to be €500 000. The number of visits to a physi-
cian in an outpatient department was 490, the cost of which
was estimated to be €130 000. The number of outpatient visits
per individual varied between 0 and 10 (median, 3), and 79
patients (53%) were hospitalized (median, 5 days; range, 1–T
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60 days). The total number of days in hospital for the entire
study group was 603. Diagnosis-related group weights varied
from 0.3104 to 1.8067 (median, 0.7825). The estimated total
cost of hospital care was €330 000, i.e. €4200 per patient. (For
comparison, the estimated costs of hospital care were €2800
per patient for pneumonia, €2300 per patient for viral meningi-
tis, and €5200 per patient for sepsis). Children under 8 years
of age were often treated with ceftriaxone administered intra-
venously once daily by a nurse in primary healthcare. In this
study, 509 ceftriaxone days were registered, resulting in an
estimated cost of €38 000.
Of the adult patients aged 16–64 years, 26 (51%) received
sickness beneﬁts from the Social Insurance Agency (range,
4–528 days; median, 32 days). The mean cost of sickness
beneﬁts was €4600 per patient. Temporary parental beneﬁts
were granted to the parents of 39 (51%) of the children
(range, 0.25–19 days; median, 5 days). The estimated total
cost of social beneﬁts was €134 000 (€2000 per patient).
Discussion
The number of NB cases veriﬁed by CSF analysis increased
from 5/100 000 to 10/100 000 inhabitants/year during the
years 2000–2005 in Jo¨nko¨ping County. The number of NB
cases during the ﬁrst part of the study period was 5–6/
100 000 inhabitants, which is approximately half as many as
reported previously [1]. This discrepancy can be explained
by the fact that we only included cases veriﬁed by CSF analy-
sis, whereas Berglund et al. [1] included patients diagnosed
with NB on the basis of either CSF ﬁndings or clinical symp-
toms and anti-Borrelia antibodies in serum. There are proba-
bly a number of patients who, during this study period, were
treated with antibiotics for a suspected NB infection, and for
whom the diagnosis was based on symptoms and the pres-
ence of Borrelia-speciﬁc antibodies in serum. The true num-
ber of NB cases in the county can thus be assumed to be
even higher than 10/100 000 inhabitants/year.
The increase in NB cases may be explained by greater
awareness of Borrelia infections, both in the general popula-
tion and among physicians. However, there might well be a
real increase in NB cases, and there are several plausible
explanations for this, i.e. a milder and more humid climate
in the region [15,16] that may be favourable to the
ticks [17,18], and increasing populations of fallow deer and
wild boars in the county during the study period [19–23]
(P. Kjellander, Grimso Wildlife Research Centre, Swedish
University of Agricultural Sciences; January 2008, personal
communication).
The data on clinical manifestations of NB, age and sex dis-
tribution, laboratory ﬁndings and the frequency of observed
tick bites and erythema migrans are mainly in line with ear-
TABLE 2. Duration of post-treatment symptoms in relation to sex, age and duration of symptoms before treatment
Patient groupa, n = 106b
A
n = 26
B
n = 33
C
n = 33
D
n = 14
Males, no. (%) 16 (61.5) 25 (75.8) 21 (63.6) 6 (42.9)
Females, no. (%) 10 (38.5) 8 (24.2) 12 (36.4) 8 (57.1)
Age (years), median (range)c 8 (4–66) 12 (3–79) 22 (3–85) 56.5 (10–64)
Duration of symptoms before
treatment (weeks), median (range)c
2 (0.1–8) 2.5 (0.5–6) 3 (0.1–36) 5.5 (2–77)
aGroups according to duration of post-treatment symptoms: A, 0–2 weeks; B, 2–4 weeks; C, 1–6 months; D, >6 months.
b106/150 patients (where data were available).
cSigniﬁcant differences between groups, except between groups B and C regarding age.
TABLE 3. Patients categorized according to time to recov-
ery after start of antibiotic treatment, in relation to symp-
toms with which they presented at the time of lumbar
puncture (%)
Symptom
Patient groupa, n = 106b
A
n = 26
B
n = 33
C
n = 33
D
n = 14
Headache 58 42 36 43
Fatigue 58 49 49 36
Fever 31 30 15 14
Neck pain 39 46 30 43
Vertigo 0 6 9 29
Concentration
difﬁculties
0 0 6 14
Radiculitis
Leg 15 21 21 57
Arm 4 12 9 29
Trunk 8 3 9 36
Muscle/joint pain 35 42 61 86
Paresthesia 4 15 33 57
Facial palsy 46 61 55 7
Other cranial
nerve palsy
0 6 6 7
aGroup A, 0–2 weeks; group B, 2–4 weeks; group C, 1–6 months; group D,
>6 months.
b106/150 patients (where data were available).
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lier observations [24–27]. However, some particularly inter-
esting ﬁndings should be pointed out. As many as 80% of the
patients had an elevated CSF albumin/serum albumin ratio,
an indicator of impairment of the blood–brain barrier. The
highest IgG indices were found among the four patients
with the longest duration of symptoms prior to treatment
(9–78 months). These four patients had no pleocytosis,
although it cannot be excluded that an earlier pleocytosis
had resolved by the time of the lumbar puncture, probably
reﬂecting the natural course of the disease. They reported
mainly unspeciﬁc symptoms.
Patients with a CSF MNC count of >284 cells/lL (the
upper quartile) most frequently reported symptoms of men-
ingitis and distinct symptoms such as facial palsy and fever.
Also, in their case, the median duration of symptoms before
treatment was shortest. Patients under the age of 40 years
had signiﬁcantly higher MNC counts in CSF than patients
aged over 40 years. The risk of developing long-lasting post-
treatment symptoms increased with age. One could specu-
late that young individuals can mobilize a strong and rapid
inﬂammatory response to the Borrelia infection, causing more
distinct clinical symptoms, which in turn lead to early diagno-
sis and treatment as well as effective elimination of bacteria.
Accordingly, a strong initial inﬂammatory response has previ-
ously been demonstrated to be associated with good prog-
nosis in borreliosis [28–32]. In contrast, older patients show
a less pronounced inﬂammatory response, and they often
present with more vague symptoms, which might delay diag-
nosis and treatment.
Our ﬁndings emphasize the importance of CSF analysis for
the diagnosis of NB, as 17% of the patients presented with
elevated levels of Borrelia-speciﬁc antibodies in CSF but not
in serum. Repeated sampling was not performed in our
study, so we cannot establish whether these patients devel-
oped antibodies in serum later on. However, without a diag-
nostic lumbar puncture, these patients might have been
misdiagnosed. Earlier studies [7], as well as our data, further
indicate that the duration of symptoms before treatment
might be of importance for the clinical outcome.
Post-treatment symptoms lasting more than 6 months
were reported by 13% of the patients (14/106). The clinical
and laboratory ﬁndings in the acute phase characterizing this
patient group were advanced age, long duration of symptoms
prior to treatment, high levels of Borrelia-speciﬁc IgG in CSF,
symptoms of radiculitis, especially radiculitis involving the
lower extremities, and unspeciﬁc symptoms, i.e. muscle and
joint pain, paresthesia, vertigo and concentration distur-
bances.
NB has important economic consequences, in terms of
both healthcare and social beneﬁts. If an NB patient is diag-
nosed at an early stage of the disease, outpatient treatment
with oral doxycycline for 10–14 days is sufﬁcient in most
cases [33]. Early treatment is associated with quick recovery
and, consequently, a shorter period of sickness beneﬁts.
There are, of course, limitations to this retrospective
study, such as a presumable bias both in reported and in
documented symptoms. It was not possible to obtain data
on time to recovery for all patients. However, the data
were available in a substantial number of cases and, further-
more, our data are in line with those of previous prospective
studies [1], supporting the accuracy of the results.
In conclusion, the number of NB cases seems to have
increased in Jo¨nko¨ping County during the years 2000–2005.
It appears to be relevant and important to follow the epide-
miological development of NB in the future, as continuing
changes in climate and the tick-feeding fauna are expected.
Symptoms and CSF ﬁndings seem to differ between younger
and older individuals, with a tendency for there to be more
distinct clinical symptoms and a more pronounced inﬂamma-
tory response in the central nervous system in the younger.
As many as 17% of the NB patients in this study had Bor-
relia-speciﬁc antibodies detectable in CSF but not in serum
at the time of the lumbar puncture, emphasizing the impor-
tance of CSF analysis for early NB diagnosis. The costs of
healthcare and social beneﬁts related to NB are quite impor-
tant, especially in patients with unspeciﬁc and long-lasting
symptoms.
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